H.C. Wainwright analyst Edward White reiterated a Buy rating on Aura Biosciences Inc (AURA – Research Report) today and set a price target of $22.00.
Edward White has given his Buy rating due to a combination of factors including the promising results from Aura Biosciences Inc’s Phase 1 trial of bel-sar in treating non-muscle invasive bladder cancer (NMIBC). The trial demonstrated encouraging outcomes, particularly in patients receiving bel-sar with light activation, where a significant number showed complete clinical responses and tumor shrinkage. The drug’s potential to alter the treatment landscape for early-stage bladder cancer is supported by its well-tolerated safety profile, with no serious adverse events reported.
Additionally, Edward White’s valuation considers the future revenue potential of bel-sar across various indications, including primary choroidal melanoma and other ocular oncology conditions. The financial forecasts, which include a projected launch in 2030 and sales estimates, underpin the Buy rating. The analysis employs a net present value approach, factoring in probabilities of success for different indications and a price-to-sales multiple that aligns with industry peers, further supporting the positive outlook for Aura Biosciences Inc.